Agustin A Garcia

Agustin A Garcia

UNVERIFIED PROFILE

Are you Agustin A Garcia?   Register this Author

Register author
Agustin A Garcia

Agustin A Garcia

Publications by authors named "Agustin A Garcia"

Are you Agustin A Garcia?   Register this Author

39Publications

990Reads

22Profile Views

Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study.

Arch Gynecol Obstet 2019 Jun 1;299(6):1641-1649. Epub 2019 Mar 1.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, 2020 Zonal Avenue, IRD520, Los Angeles, CA, 90089, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-019-05104-0DOI Listing
June 2019

Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.

J Ultrasound Med 2017 May 2;36(5):901-911. Epub 2017 Feb 2.

Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7863/ultra.16.05060DOI Listing
May 2017

Value of routine staging imaging studies for patients with stage III breast cancer.

J Surg Oncol 2016 Dec 19;114(8):917-921. Epub 2016 Sep 19.

Department of Hematology/Oncology, Louisiana State University, New Orleans, Louisiana.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.24436DOI Listing
December 2016

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

J Clin Oncol 2015 May 6;33(14):1609-19. Epub 2015 Apr 6.

Denise A. Yardley, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Robert Weaver, Florida Cancer Specialists, Tampa, FL; Michelle E. Melisko, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco; Scott Cruickshank, Scott Cruickshank & Associates, Santa Barbara; Agustin A. Garcia, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA; Mansoor N. Saleh, Georgia Cancer Specialists, Sandy Springs, GA; Francis P. Arena, New York University Langons Arena Oncology, Lake Success; Tessa Cigler and Linda T. Vahdat, Weill Cornell Medical College, New York, NY; Andres Forero, University of Alabama, Birmingham, AL; Alison Stopeck, University of Arizona Cancer Center, Tucson, AZ; Dennis Citrin, Cancer Treatment Centers of America/Midwestern Regional Medical Center, Zion; Ira Oliff, Orchard Healthcare Research, Skokie, IL; Rebecca Bechhold, Oncology Hematology Care, Cincinnati, OH; Randa Loutfi, Henry Ford Health System, Detroit, MI; and Elizabeth Crowley, Jennifer Green, Thomas Hawthorne, Michael J. Yellin, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.2959DOI Listing
May 2015

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

N Engl J Med 2015 Mar;372(10):923-32

From the Cleveland Clinic Foundation, Cleveland (H.C.F.M.); SWOG Cancer Research Group Statistical Center, Fred Hutchinson Cancer Research Center (J.M.U., W.E.B.), and Seattle Cancer Care Alliance and University of Washington (J.G.) - all in Seattle; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC (K.-A.P., P.A.F.), Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) (K.-A.P., P.A.F., J.F.F.), Calvary Mater Hospital, Newcastle, NSW (F.B., J.M.L., J.F.F.), and University of Sydney, Sydney (F.B.) - all in Australia; International Breast Cancer Study Group (IBCSG), Bern, Switzerland (K.-A.P., P.A.F.); National Institute of Oncology, Budapest, Hungary (E.H.); Auckland Regional Cancer and Blood Service, Auckland, New Zealand (D.P.); Fox Chase Cancer Center, Philadelphia (L.J.G.); Instituto de Enfermedades Neoplasicas (H.L.G.) and Oncosalud SAC (C.S.V.), Lima, Peru; Dana-Farber Cancer Institute (A.H.P., R.D.G.) and IBCSG Statistical Center (R.D.G.) - both in Boston; Wichita Community Clinical Oncology Program, Wichita (S.R.D.), and University of Kansas, Westwood (C.J.F.) - both in Kansas; University of Southern California Norris Cancer Center, Los Angeles (A.A.G.), the Angeles Clinic and Research Institute, Santa Monica (S.M.), and University of California at Irvine Chao Family Comprehensive Cancer Center, Orange (F.L.M) - all in California; National Cancer Institute, Division of Cancer Prevention, Bethesda, MD (L.M.); M.D. Anderson Cancer Center, Houston (G.N.H.); and Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL (K.S.A.).

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/obgynsurvey/2015/06000/Gosereli
Web Search
http://www.nejm.org/doi/abs/10.1056/NEJMoa1413204
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1413204DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405231PMC
March 2015

Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.

Cancer Chemother Pharmacol 2014 Dec 6;74(6):1227-34. Epub 2014 Nov 6.

Division of Medical Oncology, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2600-zDOI Listing
December 2014

Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer.

Cancer Invest 2012 May 2;30(4):295-9. Epub 2012 Apr 2.

Kenneth Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/07357907.2012.657812DOI Listing
May 2012

[Description of Melolonthidae (Coleoptera) third instar larvae associated to Agave tequilana var. Azul and their population fluctuation in Jalisco, Mexico].

Neotrop Entomol 2009 Nov-Dec;38(6):769-80

Entomología, Campus Montecillo, Colegio de Postgraduados, 56230 Montecillo, Estado de México.

View Article

Download full-text PDF

Source
March 2010

A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group.

Gynecol Oncol 2008 Oct;111(1):22-6

Division of Medical Oncology, University of Southern California, Los Angeles, CA 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2008.06.013DOI Listing
October 2008

Current status of signal transduction modulators in the treatment of gynecologic malignancies.

Curr Treat Options Oncol 2007 Dec;8(6):383-92

Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-007-0051-zDOI Listing
December 2007

Bevacizumab in the management of solid tumors.

Expert Rev Anticancer Ther 2007 Apr;7(4):433-45

University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/14737140.7.4.433
Publisher Site
http://dx.doi.org/10.1586/14737140.7.4.433DOI Listing
April 2007

Update on aromatase inhibitors in breast cancer.

Curr Opin Obstet Gynecol 2006 Feb;18(1):41-6

Division of Hematology and Oncology, Cedars Sinai Medical Center, Los Angeles, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.gco.0000192973.54105.86DOI Listing
February 2006

Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.

Cancer Invest 2005 ;23(8):665-70

Division of Medical Oncology, University of Southern California Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90048, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357900500359877DOI Listing
January 2006

Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis.

Invest New Drugs 2006 Jan;24(1):79-83

University of Southern California Keck School of Medicine, Kenneth Norris Jr. Comprehensive Cancer Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-005-4542-0DOI Listing
January 2006

Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.

Cancer Chemother Pharmacol 2005 Jul 5;56(1):75-82. Epub 2005 Apr 5.

Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-004-0940-9DOI Listing
July 2005

Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.

Gynecol Oncol 2005 Mar;96(3):810-7

Breast Cancer Program, Cedars Sinai Medical Center, Women's Cancer Research Institute, 8700 Beverly Boulevard Room 290 W, Los Angeles, CA 90048, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2004.11.037DOI Listing
March 2005

Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.

Int J Gastrointest Cancer 2003 ;34(2-3):79-86

University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1385/IJGC:34:2-3:079
Publisher Site
http://dx.doi.org/10.1385/IJGC:34:2-3:079DOI Listing
January 2005

Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer.

Gynecol Oncol 2004 May;93(2):493-8

University of Southern California, Keck School of Medicine, Kenneth Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2004.02.007DOI Listing
May 2004

Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group study.

Invest New Drugs 2002 Nov;20(4):383-7

Division of Medical Oncology, University of Southern California/Norrris Comprehensive Cancer Center, Los Angeles 90089, USA.

View Article

Download full-text PDF

Source
November 2002